Published on 7 Feb 2024 on Pharmaceutical Executive Magazine
The agreement, which is still subject to closing conditions, says that Novartis will pay about $73-per-share (68 Euros-per-share), for a total of $2.9...
Start tracking your investments with Statfolio
We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this...
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. ...
We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we ar...
Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 7....
* Right now, we’re issuing “Double... Express is an advertising partner of Motley Fool Money. Bra...
Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year...
Plus, we'll get the personal income and spending report, which includes the Fed's preferred measu...
Swiss luxury conglomerate Richemont’s stock market value surpassed 100 billion Swiss francs ($110...
(Bloomberg) -- Donald Trump opened his second term as US president with a market-jolting...